top of page
We provide a novel cancer immunotherapy technology.
General
Medical
NEWS
04/01/2026
国立大学法人東京科学大学（湯浅英哉 生命理工学院教授）との共同研究契約を締結しました。 ドラッグリポジショニングによる抗腫瘍化合物に関する研究を開始します。
03/04/2025
We have received an assignment of a patent for the treatment of refractory cancer (pancreatic cancer, etc.) with three existing pharmaceuticals. The results of an investigator-initiated clinical trial in which two (Nivolumab + Metformin) of the three drugs described in the patent were administered have showed survival of more than 7 years in a patient among advanced pancreatic cancer （Sato R, Hotta K, Kubo T, et al. (February 14, 2025) Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Cureus 17(2). We are going to license the treatment method using the three-drug administration described in the patent to medical institutions from now on.
02/14/2025
Our headquater has moved with business expansion.
12/19/2024
Interview with CEO Yasuyuki Ishii about Japanese cedar pollen allergy was puplished in Jomo newspaper.
01/11/2024
Our president and CEO, Yasuyuki Ishii, spoke at 20th Japanese society of CART Meeting on Dec. 9th, 2023.
bottom of page
